Navigation Links
Sirius Genomics Announces Issuance of U.S. Patent

Sirius Genomics Announces Issuance of U.S. Patent

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Medical Pharmaceuticals Click to view news release full screen  

Sirius Genomics Announces Issuance of U.S. Patent


VANCOUVER, Oct. 26 /PRNewswire/ - Sirius Genomics, a developer of companion diagnostics, announced today that U.S. Patent # 7,820,376 entitled "Protein C Polymorphisms" has been issued by the United States Patent and Trademark Office. The patent relates to a novel use of a Single Nucleotide Polymorphism (SNP) located in the Protein C gene.

"The patent covers methods of predicting outcome or prognosis in sepsis, and other related conditions, by determining a subject's genotype at the SNP. This patent issuance further strengthens Sirius' patent portfolio and position as a developer of companion diagnostics," stated Dr. Jennifer Kaufman-Shaw, Vice President, Intellectual Property at Sirius Genomics.

"Sirius Genomics' steadily expanding patent estate stems from discoveries made from the Company's focused approach in the identification and validation of genetic markers linked to drug response. Our focus is on improving outcomes for patients treated with various classes of drugs used in the acute care setting," stated Chris Wagner, President and CEO of Sirius Genomics.

Sirius' intellectual property portfolio includes patent families related to several therapies available and under development for sepsis and other acute conditions.  About Sirius Genomics:
Sirius Genomics develops companion diagnostics (CDx) that are closely tied to therapeutic decisions, leading to better patient outcomes through personalized medicine. Sirius generates value by improving the safety and effectiveness of pharmaceutical compounds. The Company correlates patient genetics with clinical outcomes, leading to proprietary and commercially viable CDx products that enable better drug treatment. The Company's first product is a genetic predictor of response to treatment for sepsis, a severe blood infection. Learn more at href="">

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.

SOURCE Sirius Genomics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sirius Genomics Announces New Collaboration with UK Critical Care Genomics Group
2. Sirius Genomics to Present at Invest Northwest Conference
3. Sirius Genomics Announces 2009 Board of Directors
4. Dr. Robert Lanza is Featured Guest on Deepak Chopras SIRIUS XM Stars Radio Show
5. Sirius Genomics Announces Change in Leadership
6. Learn Proven Practices to Measure, Align and Transform at SiriusDecisions Sales and Marketing Summit 2010
7. Industry Leaders from Blue Coat, Oracle, Polycom, Siemens and Taleo Headline SiriusDecisions Sales and Marketing Summit 2010
8. Sirius Genomics Announces Appointment of Senior Director of Business Development
9. Rosetta Genomics Announces Conference Call and Webcast of Second Quarter Financial Results
10. DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature
11. Rosetta Genomics Reports Second Quarter 2008 Financial Results
Post Your Comments:
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS ... the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The company, ... proud to add Target to its list of well-respected retailers. This list includes ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... HOUSTON , June 23, 2016 ... agreement with the Cy-Fair Sports Association to serve ... of the agreement, Houston Methodist Willowbrook will provide ... education and connectivity with association coaches, volunteers, athletes ... partner with the Cy-Fair Sports Association and to ...
Breaking Biology Technology:
(Date:6/21/2016)... , June 21, 2016 NuData ... the new role of principal product architect and ... the director of customer development. Both will report ... technical officer. The moves reflect NuData,s strategic growth ... response to high customer demand and customer focus ...
(Date:6/16/2016)... SAN FRANCISCO , June 16, 2016 /PRNewswire/ ... Market size is expected to reach USD ... report by Grand View Research, Inc. Technological proliferation ... and banking applications are expected to drive the ... ) , The development of ...
(Date:6/9/2016)... -- Perkotek an innovation leader in attendance control systems is proud to announce the introduction ... to make sure the right employees are actually signing in, and to even control ... ... ... ...
Breaking Biology News(10 mins):